stockrowCelldex Therapeutics, Inc.
CLDX Healthcare Biotechnology
Celldex Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.5 million, down 78.0% from fiscal 2024.
- Revenue
- −96.8%
- EPS
- −10.6%
- Free cash flow
- −35.5%
Quarter to June 2026, against a year earlier
Follow CLDX
Alert me
Celldex Therapeutics, Inc. (CLDX) Net income
Celldex Therapeutics, Inc.'s net income for fiscal 2025 was −$258.8M, compared with −$157.9M in fiscal 2024. Over the twelve months to 30 June 2026 it was −$300.5M. Over the past ten years it has ranged from −$258.8M (fiscal 2025) to −$50.9M (fiscal 2019) — the current reading is the lowest in ten years. Net income has fallen for 6 consecutive fiscal years. Celldex Therapeutics, Inc. ranks 560th of 605 Biotechnology companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | −$258.8M | — |
| FY2024 | −$157.9M | — |
| FY2023 | −$141.4M | — |
| FY2022 | −$112.3M | — |
| FY2021 | −$70.5M | — |
| FY2020 | −$59.8M | — |
| FY2019 | −$50.9M | — |
| FY2018 | −$151.2M | — |
| FY2017 | −$93.0M | — |
| FY2016 | −$128.5M | — |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Jun 2026 | −$73.5M | — |
| Mar 2026 | −$78.7M | — |
| Dec 2025 | −$81.3M | — |
| Sep 2025 | −$67.0M | — |
| 42 more quarters | Free account |
Against its own ten years
Net income against peers
| Company | Net income |
|---|---|
| AUPH Aurinia Pharmaceuticals Inc compare | $314.3M |
| ADMA ADMA Biologics Inc compare | $182.4M |
| VCEL Vericel Corporation compare | $33.3M |
| PVLA Palvella Therapeutics, Inc. compare | −$61.7M |
| PHVS Pharvaris N.V. compare | −$193.1M |
| IMNM Immunome, Inc. compare | −$254.3M |
| CLDX Celldex Therapeutics, Inc. | −$300.5M |
| VERA Vera Therapeutics, Inc. compare | −$401.9M |
| BHVN Biohaven Ltd. compare | −$542.7M |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item
More on CLDX
- Revenue
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement